Friday, August 19, 2011

Focus on LanthaScreen®

Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET) is a preferred fluorescent assay format in drug discovery laboratories. TR-FRET assays are less susceptible to compound interference than other assay formats and may be applied to multiple target classes. To support this technology focus, Life Technologies has developed LanthaScreen® biochemical and cellular assays to measure kinase activity, compound binding, and post-translation modification events, such as phosphorylation and acetylation of substrates, in cell signaling. LanthaScreen® assays utilize terbium and europium chelates as FRET donors. Terbium chelate is used as a donor for fluorescein and GFP and europium chelate is a donor for Alexa Fluor® 647.

Schematic of LanthaScreen® kinase activity assay using traditional peptide substrates. A fluorescein-labeled kinase substrate peptide is incubated with kinase and ATP. Terbium or europium-labeled antibody is then added and phosphorylation detected by an increase in the TR-FRET value. Because the substrate is directly labeled, there is no need to add streptavidin-APC. Additionally, unlike other europium-based systems, there is no requirement to add high concentrations of potassium fluoride, which can potentially disrupt antibody–product interactions.
The following BMG LABTECH microplate readers have received LanthaScreen® certification from Invitrogen Corp.
PHERAstar FS
PHERAstar Plus
POLARstar Omega
FLUOstar Omega

For more information on the LanthaScreen® Assay visit: http://www.bmglabtech.com/technology/lanthascreen.cfm

LanthaScreen is a registered trademark of Invitrogen Corp.

No comments:

Post a Comment

Please let us know what you think...